Komsun Suwannarurk MD*, Yudthadej Thaweekul MD*, Karicha Mairaing MD*, Yenrudee Poomtavorn MD*, Kaan Tangtiang MD**, Wichet Piyawang MD**, Kornkarn Bhamarapravatana PhD***
Affiliation : The abstract of this manuscript was presented on April 12-15, 2015 as a poster presentation at the RCOG World Congress 2015, Joint RCOG/RANZCOG Event, Brisbane, Australia * Gynaecological Oncology Unit, Department of Obstetrics and Gynaecology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand ** Department of Radiology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand *** Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
Background : Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), has
been approved for concurrent treatment with first line chemotherapy in advanced epithelial ovarian cancer.
Case Report: A case of an advanced stage epithelial ovarian cancer (EOC) receiving a combination of bevacizumab,
carboplatin and paclitaxel chemotherapy was reported. A 44-year-old woman was presented with abdominal discomfort and
distention for 4 months. Bilateral 12 cm diameter ovarian tumors were diagnosed as FIGO stage IIIc after surgical staging
operation. Histopathology report showed the mixed type of serous and endometriod adenocarcinoma. The patient was then
started on carboplatin/paclitaxel combination chemotherapy for 6 cycles after surgery every 3 weeks. Bevacizumab (7.5 mg/
m2) was concurrently administered with chemotherapy every 3 weeks starting from the 2nd cycle. A complete remission was
achieved after the end of the chemotherapy treatment. Bevacizumab was continued for one year after the completion of the
standard chemotherapy. Bone marrow suppression, hypertension and proteinuria were not found during Bevacizumab
treatment. At bevacizumab treatment completion, a platinum-sensitive recurrent ovarian cancer was diagnosed at the two
weeks post program routine check-up. The patient was counseled to start second line chemotherapy treatment and has yet to
come back with her decision.
Conclusion : Combination of bevacizumab, carboplatin and paclitaxel for first line chemotherapy in advanced EOC in this
case had no serious side effects and need further study.
Keywords : Ovarian cancer, Bevacizumab, Carboplatin, Paclitaxel
JOURNAL OF THE MEDICAL ASSOCIATION OF THAILAND
4th Floor, Royal Golden Jubilee Building,
2 Soi Soonvijai, New Petchburi road,
Bangkok 10310, Thailand.
Phone: 0-2716-6102, 0-2716-6962
Fax: 0-2314-6305
Email: editor@jmatonline.com
» Online Submissions » Author Guidelines » Copyright Notice » Privacy Statement
» Journal Sponsorship » Site Map » About this Publishing System
© MEDICAL ASSOCIATION OF THAILAND. All Rights Reserved. The content of this site is intended for health professionals.